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Abstract
Background and Objective Elderly patients with diabetes
are more vulnerable to the occurrence and effects of
hypoglycaemia; therefore, treatments with low risk of
hypoglycaemia are preferred in this population. This study
aimed to compare hypoglycaemia rates between insulin
degludec (IDeg) and insulin glargine (IGlar) in elderly
patients.
Methods Hypoglycaemia data from patients C65 years of
age with type 1 (T1DM) or type 2 (T2DM) diabetes from
seven randomised, treat-to-target phase IIIa trials were
used to compare IDeg and IGlar in a pre-planned meta-
analysis. Overall, 917/4345 (21 %) randomised patients in
the seven trials were elderly (634 IDeg, 283 IGlar). Overall
confirmed hypoglycaemia was defined as \3.1 mmol/L or
severe hypoglycaemia (symptoms requiring external
assistance). Nocturnal hypoglycaemia included confirmed
episodes from 0001 to 0559 hours (inclusive). Treatment
comparisons of hypoglycaemia in T1DM patients were not
performed due to low numbers of elderly patients with
T1DM randomised (43 IDeg, 18 IGlar); statistical com-
parisons were also not made for severe hypoglycaemia due
to the low number of events.
Results In elderly patients with T2DM, the rate of overall
confirmed hypoglycaemia was significantly lower with
IDeg than IGlar [estimated rate ratio (ERR) 0.76 (0.61;
0.95)95 % CI]; nocturnal confirmed hypoglycaemia was also
significantly lower with IDeg [ERR 0.64 (0.43;
0.95)95 % CI]. Confirmed hypoglycaemia occurred in the
majority of T1DM patients, whereas severe episodes
occurred infrequently and at similar rates in both treatment
groups in T1DM and T2DM.
Conclusion Results of this pre-planned meta-analysis in
elderly patients with diabetes demonstrate a significant
reduction in hypoglycaemic events with IDeg relative to
IGlar.
1 Introduction
The prevalence of diabetes in the elderly is high; current
estimates indicate that in the US, 26.9 % of people
C65 years of age are diagnosed with the condition [1]. As
the US population ages and the rates of individuals who are
overweight or obese continue to rise, both the prevalence
and burden of diabetes in the elderly is expected to increase
substantially over the next several decades [2].
The American Diabetes Association (ADA) recom-
mends that glycaemic goals for elderly patients with dia-
betes should be individualised, based on the presence or
absence of cognitive impairment, functional impairment,
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major comorbidities and limited life expectancy [3–5].
Medical management of elderly patients with diabetes is
challenging due to a number of factors [6–8]. For example,
elderly patients are more likely to have diabetes that is
complicated by end-organ damage and, in general, long
duration of disease is associated with defective glucose
counter-regulation leading to increased risk of hypogly-
caemia and hypoglycaemia unawareness.
Episodes of severe hypoglycaemia in the elderly have
been associated with increased risk of cardiac autonomic
dysfunction [9], falls [10, 11], and dementia [12]. More-
over, elderly patients often live alone, which may make the
consequences of hypoglycaemia and hypoglycaemic
unawareness even more detrimental. For these reasons, a
2012 joint position statement by the ADA and the Euro-
pean Association for the Study of Diabetes (EASD) stated
that, in this at-risk population, drug selection should favour
agents that minimise the risk of hypoglycaemia [4].
Insulin therapy is required to achieve glycaemic control
in all patients with type 1 diabetes (T1DM) and in many
patients with type 2 diabetes (T2DM) who are not ade-
quately controlled with oral antidiabetic drugs (OADs) or
glucagon-like peptide-1 (GLP-1) receptor agonists. While
insulin is effective for all patients with diabetes, hypogly-
caemia and fear of hypoglycaemia associated with insulin
have resulted in delays in both initiation and intensifica-
tion, thus limiting patients’ well-being and their ability to
reach glycaemic targets [13].
Insulin degludec (IDeg) is a new basal insulin with an
ultra-long duration of action that, upon injection into sub-
cutaneous tissue, forms a depot of soluble multi-hexamers
from which insulin monomers are slowly and continuously
absorbed into the circulation [14, 15]. In line with clinical
pharmacology findings [16–18], IDeg improved glycaemic
control with HbA1c reductions that were non-inferior to
insulin glargine (IGlar), but with a significantly lower rate
of nocturnal hypoglycaemia in the three 1-year phase III
trials in T1DM and T2DM [19–21].
A prospective, pre-planned meta-analysis of pooled
patient-level data from all seven IDeg phase III trials with
IGlar as the comparator confirmed the hypoglycaemia
results of the individual trials [22]. The objective of this
pre-planned meta-analysis was to compare rates of hypo-
glycaemia between IDeg and IGlar, specifically in elderly
patients C65 years of age.
2 Methods
2.1 Design of Trials Included in the Meta-analysis
The IDeg phase III clinical development programme
(BEGIN) included seven randomised, open-label, treat-to-
target trials of either 26 or 52 weeks’ duration comparing
once-daily IDeg to once-daily IGlar [19–21, 23–26].
Table 1 summarises the design features of each trial. Two
trials (Trials 3583 and 3770) enrolled patients with T1DM
and five (Trials 3582, 3668, 3672, 3579 and 3586) enrolled
patients with T2DM.
All seven trials enrolled patients who were at least
18 years of age (20 years in Japan), with no upper age
limit; data from elderly patients C65 years of age were
included in this meta-analysis. The definition of elderly
patients as those who were C65 years of age was chosen
to remain consistent with US FDA guidance [27]. Rele-
vant to this analysis of hypoglycaemia, hypoglycaemic
unawareness, or recurrent hypoglycaemia defined as more
than one severe hypoglycaemic episode in the last year,
were exclusion criteria in the seven clinical trials.
Moreover, hypoglycaemic episodes that occurred during
the treatment period and posed a safety concern in the
opinion of the investigator were criteria for withdrawal. In
addition, patients with serious comorbidities were
excluded.
Two trials (T1DM Trial 3770 and T2DM Trial 3668)
included an additional dosing arm, in which the extremes
of once-daily dosing of IDeg were tested by alternating
morning and evening dosing from day to day [23, 24]. It
was prespecified that data from elderly patients randomised
to this enforced and atypical flexible dosing regimen were
not included in the meta-analysis because this type of
regimen does not reflect the intended use of IDeg in clinical
practice.
The primary objective of all seven trials, to demonstrate
non-inferiority of IDeg to IGlar with respect to reduction in
HbA1c [19–21, 23–26], was achieved by titrating both IDeg
and IGlar for each individual patient to reach a pre-
breakfast plasma glucose target of \5 mmol/L (\90 mg/
dL) using the T1DM and T2DM algorithms of the IDeg
programme (algorithm details are available in individual
trial publications). HbA1c non-inferiority was a prerequisite
to compare the key secondary endpoint of hypoglycaemia
[28]. Adherence to the titration algorithm was monitored
by a titration committee blinded to treatment.
The seven trials included in this meta-analysis were
conducted in accordance with the Declaration of Helsinki
[29] and Good Clinical Practice [30]. Protocols were
approved by independent ethics committees/institutional
review boards prior to the trials, and patients signed
informed consent. Trials were conducted between Sep-
tember 2009 and December 2010, and are registered with
ClinicalTrials.gov with the following numbers:
NCT00982228 (Trial 3583), NCT01079234 (Trial 3770),
NCT00972283 (Trial 3582), NCT01006291 (Trial 3668),
NCT00982644 (Trial 3579), NCT01068665 (Trial 3672)
and NCT01059799 (Trial 3586).
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2.2 Reporting and Classification of Hypoglycaemic
Episodes
Hypoglycaemic episodes were reported by patients either
as the result of routine blood glucose monitoring or
recognised symptoms. Patients performed routine blood
glucose tests using glucose meters calibrated to give
plasma glucose results on 3 consecutive days before visits
(daily in Trial 3770) and recorded the values in patient
diaries. Patients tested their glucose either before and 90
minutes after meals, as well as at bedtime and in the middle
of the night (9-point profile), or before meals and at bed-
time (4-point profile) multiple times during the trials. In
addition, patients were instructed to self-measure their
blood glucose with their trial-supplied glucose meter
whenever they experienced symptoms of hypoglycaemia.
Patients’ self-reported information related to episodes of
hypoglycaemia in their diaries, which included date and
time of the hypoglycaemic episode, the presence or
absence of symptoms, and if the episode was self-treated.
Hypoglycaemic episodes were classified as severe,
confirmed or nocturnal confirmed. Severe episodes
required assistance from another person to administer
carbohydrates or glucagon and did not necessarily have an
associated blood glucose measurement. Confirmed hypo-
glycaemic episodes were either severe episodes or those
episodes that had an associated self-measured blood glu-
cose measurement of \3.1 mmol/L (\56 mg/dL), regard-
less of the presence of hypoglycaemic symptoms.
Nocturnal confirmed hypoglycaemic episodes were any
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confirmed episodes that occurred from 0001 to 0559 hours
(both inclusive). Treatment-emergent episodes of hypo-
glycaemia were any episodes that occurred from the first
dose of trial drug up until 7 days after the last dose of trial
drug (i.e. the last trial visit).
2.3 Statistical Methodology
The number and percentage of patients with one or more
hypoglycaemic episode, the number of hypoglycaemic epi-
sodes in total, and the rate of hypoglycaemia [number of
episodes per patient-year of exposure (PYE)] were summa-
rised descriptively by treatment and by population (T1DM,
T2DM) for the various hypoglycaemia classifications (severe,
overall confirmed and nocturnal confirmed). Descriptive sta-
tistics of hypoglycaemia were presented for all patients
exposed to treatment [i.e. the safety analysis set (SAS)].
Statistical methodology for the hypoglycaemia meta-
analysis of elderly patients was identical to the primary
meta-analysis, previously described by Ratner et al. [22],
except that only patients C65 years of age at screening
were included in the analysis. The number of treatment-
emergent hypoglycaemic episodes was counted for each
subject and divided by exposure time, then analysed using
a negative binomial regression model adjusted for differ-
ences across trials, sex, geographical region, diabetes type,
antidiabetic therapy at screening and age. Hypoglycaemic
rates are expressed as the number of episodes per PYE.
Data from elderly patients in the full analysis set (FAS;
consisting of randomised patients) were analysed, and
treatment differences presented as estimated rate ratios
(ERRs) [IDeg/IGlar] with 95 % confidence intervals (CIs).
Comparisons of the rates of confirmed hypoglycaemia
and nocturnal confirmed hypoglycaemia were made for
elderly subjects in the T2DM trials and the pooled T1DM
and T2DM trials. A separate statistical analysis of hypo-
glycaemia in T1DM was not performed due to the small
number of elderly subjects in the two T1DM trials
(Table 1). Likewise, no statistical treatment comparisons of
severe hypoglycaemia were made because there were very
few episodes classified as severe in the elderly population.
The analyses of hypoglycaemia described above included
treatment-emergent hypoglycaemic episodes that occurred
during the entire trial period (total treatment period), as
specified for each trial in Table 1. In addition, separate anal-
yses of treatment-emergent hypoglycaemic events that
occurred during the maintenance period (week 16 to the end of
the trials) were conducted. The maintenance period was
included in order to show results after stable glycaemic control
and a stable insulin dose had been achieved following initial
titration, as it was believed that there might be a learning curve
for optimal titration associated with use of a new insulin
product that would likely have resolved after 16 weeks [22].
3 Results
3.1 Patients Included in the Meta-analysis
A total of 917/4345 (21 %) randomised patients in the
seven trials in the IDeg development programme that
compared once-daily IDeg with once-daily IGlar were
elderly (C65 years of age). Across the trials, the proportion
of elderly patients randomised to receive treatment ranged
from 6 to 28 % (Table 1). There was a lower proportion of
elderly patients in the two T1DM trials than in the five
T2DM trials (Table 1). Of the 917 elderly patients ran-
domised to treatment (634 IDeg, 283 IGlar), 61 had T1DM
(43 IDeg, 18 IGlar) and 856 had T2DM (591 IDeg, 265
IGlar). The larger number of elderly patients randomised to
IDeg treatment reflected the unequal randomisation of 3:1
or 2:1 to IDeg:IGlar in four of the seven trials.
Overall, completion rates were high for both T1DM and
T2DM and were similar between the IDeg and IGlar
treatment groups (Fig. 1). Patient characteristics generally
were similar across treatment groups, both for elderly
patients with T1DM and those with T2DM (Table 2).
However, compared with the IGlar group, in the IDeg
group there was a higher proportion of male patients and a
higher proportion of patients with T2DM previously treated
with basal insulin ± OADs. The mean age of elderly
patients was similar between groups, &70 years in both
T1DM and T2DM patients. The duration of diabetes was
longer in elderly patients with T1DM (&27 years) than
those with T2DM (&13 years).
For the overall population in all seven trials, non-infe-
riority was met with regard to the primary endpoint, change
in HbA1c (observed mean baseline and end-of-trial HbA1c
for each of the seven trials are provided in Table 1). Mean
basal insulin doses in elderly patients were comparable
between treatment groups (24.9 U with IDeg and 28.6 U
with IGlar in T1DM, and 42.2 U with IDeg and 37.3 U
with IGlar in T2DM).
3.2 Hypoglycaemia in Elderly Patients
Hypoglycaemic episodes are summarised descriptively by
classification, treatment, and diabetes population over the
total treatment period for individual trials and in total in
Table 3, in which the proportion of patients experiencing
hypoglycaemia and the rate (episodes per PYE) are shown.
The total observed proportion of patients with overall
confirmed hypoglycaemia during the trials appeared simi-
lar between treatment groups both in T1DM [97.7 %
(IDeg); 94.1 % (IGlar)] and T2DM [58.7 % (IDeg and
IGlar)]. Observed rates of overall confirmed hypoglycae-
mic episodes were numerically lower in one and higher in
the other of the two T1DM trials with IDeg than with IGlar
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(overall slightly higher with IDeg). Rates were lower with
IDeg in four of the five T2DM trials (overall slightly lower
with IDeg).
The total observed proportion of patients with nocturnal
confirmed hypoglycaemia was 69.8 % for IDeg and 82.4 %
for IGlar in T1DM, and 21.2 % for IDeg and 25.4 % for
IGlar in T2DM. Observed rates of nocturnal confirmed
hypoglycaemic episodes were again numerically lower in
one and higher in the other of the two T1DM trials with
IDeg (overall lower with IDeg), and were lower with IDeg
in all five T2DM trials (Table 3). Very few episodes of
severe hypoglycaemia occurred during the trials: the total
proportion of patients with severe hypoglycaemia was
9.3 % (IDeg) and 11.8 % (IGlar) in T1DM, and 2.9 %
(IDeg) and 4.2 % (IGlar) in T2DM.
Rates and proportions of patients with overall con-
firmed, nocturnal confirmed and severe hypoglycaemia
during the maintenance period are summarised descrip-
tively in Table 4. During this timeframe, when dose titra-
tions and glycaemic improvements had stabilised, there
appeared to be a lower rate of overall confirmed and noc-
turnal confirmed hypoglycaemia in patients with T1DM in
both treatment groups than during the total treatment per-
iod. Little difference was observed in severe hypoglycae-
mia rates, or in the rate of patients with T2DM
experiencing overall confirmed or nocturnal confirmed
Fig. 1 Disposition of elderly
patients (C65 years of age). AEs
adverse events, FAS full
analysis set, IDeg insulin
degludec, IGlar insulin
glargine, SAS safety analysis
set, T1DM type 1 diabetes
mellitus, T2DM type 2 diabetes
mellitus. The IDeg flexible arm
is excluded from Trials 3770
and 3668. *Two randomised
IDeg patients from one closed
trial site were excluded from the
full analysis set before the trial
was unmasked
Table 2 Patient characteristics
of elderly patients (C65 years of
age)
Full analysis set
BMI body mass index, IDeg
insulin degludec, IGlar insulin
glargine, OAD(s) oral
antidiabetes drug(s), SD
standard deviation, T1DM type




No. of patients 43 18
Female/male, n (%) 18 (41.9)/25 (58.1) 10 (55.6)/8 (44.4)
Age, years, mean ± SD 69.6 ± 3.5 69.9 ± 3.8
BMI, kg/m2, mean ± SD 26.1 ± 4.1 26.6 ± 4.6
Duration of diabetes, years, mean ± SD 28.0 ± 14.3 26.4 ± 14.6
T2DM patients
No. of patients 589 265
Female/male, n (%) 248 (42.1)/341 (57.9) 121 (45.7)/144 (54.3)
Age, years, mean ± SD 70.1 ± 3.8 69.9 ± 3.8
BMI, kg/m2, mean ± SD 29.8 ± 5.2 29.7 ± 4.8
Duration of diabetes, years, mean ± SD 13.8 ± 7.9 13.4 ± 7.3
Prior antidiabetic therapy, n (%)
OAD(s) only 368 (62.5) 182 (68.7)
Basal insulin ± OAD(s) 220 (37.4) 83 (31.3)
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hypoglycaemia during the maintenance period as opposed
to the total treatment period. The proportion of patients
experiencing hypoglycaemia was generally lower in most
trials during the maintenance period for both treatment
groups; please see Table 4 for more detail.
3.3 Treatment Comparisons of Hypoglycaemia
As previously mentioned, due to the low number of sub-
jects with T1DM (Fig. 1) and few episodes of severe
hypoglycaemia in this study, insufficient data were avail-
able to perform formal statistical analyses; hence, summary
statistics alone are presented for these situations.
Over the total treatment period and maintenance period,
respectively, elderly patients with T2DM had a 24 % [ERR
(IDeg/IGlar) 0.76 (0.61; 0.95)95 % CI] and 27 % [ERR
(IDeg/IGlar) 0.73 (0.56; 0.96)95 % CI] lower estimated rate
of overall confirmed hypoglycaemia with IDeg compared
with IGlar; both treatment comparisons were statistically
significant (Fig. 2a). Estimated rates of nocturnal con-
firmed hypoglycaemia during the total treatment period and
maintenance period were 36 % [ERR (IDeg/IGlar) 0.64
(0.43; 0.95)95 % CI] and 39 % [ERR (IDeg/IGlar) 0.61
(0.37; 1.03)95 % CI] lower with IDeg versus IGlar, respec-
tively; the treatment comparison during the total treatment
period, but not the maintenance period, reached statistical
significance (Fig. 2b).
As planned in the prespecified meta-analysis, an analysis
of the pooled population including elderly patients with
T1DM or T2DM was conducted. In this pooled population
(T1DM ? T2DM), rates of overall confirmed hypoglycae-
mia were numerically lower with IDeg than IGlar, by 18 %
in the total treatment period and by 21 % in the mainte-
nance period; neither comparison was statistically signifi-
cant (Fig. 3a). In the pooled T1DM and T2DM population,
rates of nocturnal confirmed hypoglycaemia were 35 %
lower with IDeg than IGlar in both the total and mainte-
nance periods (this comparison was statistically significant
in favour of IDeg for the total treatment period and non-
significant during the maintenance period) (Fig. 3b).
4 Discussion
The IDeg phase III development programme studied a
representative group of patients with regard to type of
disease (T1DM or T2DM), duration of diabetes, previous
treatment regimen (insulin naı¨ve or insulin treated), type of
insulin regimen studied (basal-only therapy, basal–bolus
therapy) and combining insulin with a range of oral anti-
hyperglycaemic therapies. More than one-fifth of this large
patient population were elderly (C65 years of age) as per
FDA guidance [27], and a meta-analysis of the elderly
population with T1DM or T2DM was prespecified as part
of the overall hypoglycaemia meta-analysis plan.
In the present meta-analysis, patient-level data from
more than 900 elderly patients (the majority of whom had
T2DM) showed estimated rates of overall confirmed
hypoglycaemia that were significantly lower with IDeg
than IGlar in T2DM (Fig. 2a). Consistent with these pooled
analyses, observed rates of overall confirmed hypoglycae-
mia were lower with IDeg in four of the five individual
T2DM trials (Table 3) during the total treatment period.
The proportion of subjects experiencing overall confirmed
Table 3 Overall confirmed, nocturnal confirmed and severe hypoglycaemia during the total treatment period in elderly patients, summarised by
trial
Trial Overall confirmed hypoglycaemic episodes
per PYE (% patients)
Nocturnal confirmed hypoglycaemic episodes
per PYE (% patients)
Severe hypoglycaemic episodes
per PYE (% patients)
IDeg IGlar IDeg IGlar IDeg IGlar
T1DM
3583 45.73 (96.6) 46.49 (90.0) 3.51 (75.9) 8.28 (70.0) 0.11 (10.3) 0.32 (20.0)
3770 106.04 (100.0) 66.90 (100.0) 14.25 (57.1) 12.53 (100.0) 0.15 (7.1) 0.00 (0.0)
Total 58.06 (97.7) 52.03 (94.1) 5.71 (69.8) 9.43 (82.4) 0.12 (9.3) 0.23 (11.8)
T2DM
3582 12.50 (86.3) 15.47 (86.2) 1.32 (36.1) 1.51 (44.6) 0.10 (7.3) 0.15 (12.3)
3668 4.35 (50.0) 3.58 (53.7) 0.29 (8.3) 1.02 (26.8) 0.06 (2.8) 0.06 (2.4)
3579 1.68 (50.0) 1.79 (48.6) 0.27 (13.8) 0.37 (14.3) 0.01 (0.5) 0.02 (1.4)
3672 1.06 (31.8) 2.18 (40.8) 0.14 (4.5) 0.50 (12.2) 0.00 (0.0) 0.00 (0.0)
3586 2.90 (41.0) 4.47 (66.7) 0.83 (18.1) 1.07 (28.2) 0.00 (0.0) 0.05 (2.6)
Total 6.19 (58.7) 6.89 (58.7) 0.74 (21.2) 0.91 (25.4) 0.04 (2.9) 0.07 (4.2)
Safety analysis set. Observed rates. The IDeg flexible arm is excluded in Trials 3770 and 3668
IDeg insulin degludec, IGlar insulin glargine, PYE patient-years of exposure, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
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hypoglycaemia was lower in three and higher in two of
these five trials with IDeg. The mean proportion was the
same overall for both treatment groups in T2DM, sug-
gesting that while similar proportions of patients in both
treatment arms experienced hypoglycaemia, IDeg patients
tended to experience fewer events, which is likely a result
of the ultra-long and stable pharmacokinetic profile and the
lower day-to-day variability in glucose-lowering action of
IDeg [16–18]. Rates of severe hypoglycaemia were low in
both treatment groups across trials, for both T1DM and
T2DM patients.
Nocturnal confirmed hypoglycaemia was chosen as an
endpoint because it better reflects the action of basal insulin
compared with overall confirmed hypoglycaemia, which
may be influenced by bolus insulin, meal patterns and the
physical activity level during the day. When events of noc-
turnal confirmed hypoglycaemia were analysed, a greater
difference in the relative rate of hypoglycaemia between
IDeg and IGlar in elderly patients with T2DM was observed
than for overall confirmed hypoglycaemia (Fig. 2b).
Rates of hypoglycaemia varied and were higher in some
trials than others, varying by trial population (T1DM or
T2DM, insulin naı¨ve or insulin treated), duration of dia-
betes and levels of glycaemic control at baseline as well as
the treatment regimen (basal only or basal–bolus therapy).
In both the IDeg and IGlar groups, insulin was titrated
Fig. 2 Estimated rate ratios (IDeg/IGlar) with 95 % confidence
intervals in elderly patients C65 years of age with T2DM for a overall
confirmed hypoglycaemic episodes, and b nocturnal confirmed
hypoglycaemic episodes during the total treatment period and
maintenance period. *Statistically significant, p \ 0.05. IDeg insulin
degludec, IGlar insulin glargine, T2DM type 2 diabetes mellitus.
Nocturnal confirmed episodes are the subset of overall confirmed
hypoglycaemic episodes with onset from 0001 to 0559 hours (both
inclusive). The maintenance period was from week 16 to the end of
the trials. Full analysis set
Table 4 Overall confirmed, nocturnal confirmed and severe hypoglycaemia during the maintenance period in elderly patients, summarised by
trial
Trial Overall confirmed hypoglycaemic episodes
per PYE (% patients)
Nocturnal confirmed hypoglycaemic episodes
per PYE (% patients)
Severe hypoglycaemic episodes
per PYE (% patients)
IDeg IGlar IDeg IGlar IDeg IGlar
T1DM
3583 39.72 (96.2) 43.58 (90.0) 2.95 (69.2) 7.99 (70.0) 0.06 (3.8) 0.47 (20.0)
3770 109.54 (100.0) 65.14 (85.7) 16.73 (42.9) 9.52 (71.4) 0.40 (7.1) 0.00 (0.0)
Total 48.28 (97.5) 47.38 (88.2) 4.64 (60.0) 8.26 (70.6) 0.10 (5.0) 0.39 (11.8)
T2DM
3582 11.73 (77.1) 13.55 (73.0) 1.24 (24.6) 1.25 (31.7) 0.11 (6.7) 0.10 (4.8)
3668 4.02 (29.4) 4.66 (35.3) 0.15 (2.9) 1.55 (20.6) 0.00 (0.0) 0.00 (0.0)
3579 1.78 (42.2) 2.09 (45.2) 0.34 (13.5) 0.45 (12.9) 0.01 (0.5) 0.03 (1.6)
3672 0.92 (14.6) 2.54 (27.9) 0.00 (0.0) 0.48 (9.3) 0.00 (0.0) 0.00 (0.0)
3586 2.48 (25.0) 3.95 (37.8) 0.69 (10.5) 0.85 (10.8) 0.00 (0.0) 0.00 (0.0)
Total 6.14 (47.5) 6.93 (45.6) 0.73 (15.1) 0.87 (18.0) 0.05 (2.5) 0.05 (1.7)
Safety analysis set. Observed rates. The maintenance period was from week 16 to the end of the trial. The IDeg flexible arm is excluded in Trials
3770 and 3668
IDeg insulin degludec, IGlar insulin glargine, PYE patient-years of exposure, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
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using standard algorithms to reach similar pre-breakfast
glucose targets. The majority of insulin titration and cor-
responding glycaemic reductions took place during the first
15 weeks of the trials. In the subsequent maintenance
period, during which insulin titration and insulin doses
were stable, differences in relative rates of both overall and
nocturnal hypoglycaemia appeared to be greater than dur-
ing the total treatment period (Figs. 2 and 3).
Similar to the results in the entire population of both
elderly and younger patients reported by Ratner and col-
leagues [22], the risks of overall confirmed hypoglycaemia
and nocturnal confirmed hypoglycaemia over the total
treatment period reported in this meta-analysis of elderly
patients were significantly lower for IDeg compared with
IGlar in T2DM. Hence, the hypoglycaemic benefits with
IDeg relative to IGlar demonstrated in this meta-analysis of
elderly patients were consistent with that seen in the entire
adult patient population.
Limitations of this meta-analysis include the open-label
design of the studies, which could potentially bias reporting
of hypoglycaemic episodes or insulin dosing. To attempt to
reduce reporting bias, all hypoglycaemic episodes either
were meter-confirmed with a blood glucose measurement
[PG \3.1 mmol/L (56 mg/dL)] or were severe episodes,
which by definition required assistance by a third party to
treat. The fact that this definition was independent of the
presence of symptoms is of particular relevance for elderly
patients who may have atypical, less intense, or delayed
symptoms of hypoglycaemia [31]. To address potential
investigator bias in insulin dosing, the same glycaemic tar-
gets and titration algorithms were used for both groups, and a
titration committee blinded to treatment identified and dis-
cussed deviations from the algorithm with trial investigators
to encourage adherence to the algorithms. Furthermore,
although the meta-analysis described in this report was pre-
planned, it comprised a subset of data for elderly subjects
enrolled in the larger overall phase III trials, and its con-
clusions could be strengthened further by the collection of
additional data from a prospective randomised study
designed to demonstrate the superiority of IDeg compared
with IGlar with regard to hypoglycaemia risk in the elderly.
Exclusion from the trials of patients who had hypogly-
caemic unawareness or more than one severe episode of
hypoglycaemia in the last year or who had other serious
comorbidities was another limitation, especially because
elderly patients with diabetes may be more frequently affected
by these conditions than younger patients [9, 32]. However,
this criterion for exclusion was applied for safety reasons
because these individuals would not be appropriate candidates
for intensive titration with insulin to achieve near-normal
levels of glycaemic control [\5 mmol/L (\90 mg/dL)] [4], as
was the goal of treatment in the IDeg phase III trials.
Data from dedicated clinical trials comparing basal
insulin treatments in elderly patients are lacking. A meta-
analysis of pooled patient-level data from five randomised
controlled clinical trials conducted between 1999 and 2002
compared hypoglycaemia with once-daily IGlar versus
intermediate-acting once-daily neutral protamine Hagedorn
(NPH) in insulin-naı¨ve elderly patients (C65 years) with
T2DM [32]. Although the definitions of hypoglycaemia in
this meta-analysis of elderly patients differed from those in
the present meta-analysis, episode rates appeared lower
with IGlar than NPH, both for symptomatic nocturnal
hypoglycaemia and severe nocturnal hypoglycaemia;
however, treatment differences did not reach statistical
significance [32].
Fig. 3 Estimated rate ratios (IDeg/IGlar) with 95 % confidence
intervals in elderly patients C65 years of age for the pooled
population (T1DM ? T2DM) for a overall confirmed hypoglycaemic
episodes, and b nocturnal confirmed hypoglycaemic episodes during
the total treatment period and maintenance period. *Statistically
significant, p \ 0.05. IDeg insulin degludec, IGlar insulin glargine,
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus.
Nocturnal confirmed episodes are the subset of overall confirmed
hypoglycaemic episodes with onset from 0001 to 0559 hours (both
inclusive). The maintenance period was from week 16 to the end of
the trials. Full analysis set
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5 Conclusion
Consistent with the results of the meta-analysis of the
overall patient population [22], this meta-analysis of IDeg
phase III trials demonstrated that elderly patients also
experience lower rates of hypoglycaemic episodes with
IDeg compared with IGlar, particularly during the night.
The reduced risk of hypoglycaemia found with IDeg rela-
tive to IGlar in this analysis should be taken into account
when considering insulin treatment for elderly patients
with diabetes.
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